AUTL - CIK 0001730463
Autolus Therapeutics plc (AUTL) reported net income of -$287.53M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$287.53M | -30.3% |
| FY 2024 | -$220.66M | -5.9% |
| FY 2023 | -$208.38M | -40.0% |
| FY 2022 | -$148.84M | -4.7% |
| FY 2021 | -$142.10M | -0.0% |
| FY 2020 | -$142.09M | -14.7% |
| FY 2019 | -$123.85M | -176.8% |
| FY 2018 | -$44.75M | -126.9% |
| FY 2017 |
Autolus Therapeutics plc (AUTL) reported net income of -$287.53M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2016 and fiscal 2025, Autolus Therapeutics plc's net income declined from -$12.55M to -$287.53M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$19.73M |
| -57.2% |
| FY 2016 | -$12.55M | - |